Joseph Michael Burnett, CEO, described 2025 as the start of ClearPoint Neuro’s “third phase,” called Fast. Forward., emphasizing an expanded commitment to cell and gene therapy, workflow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback